Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Abstract Advanced ovarian cancer is very responsive to first line platinum therapy, however almost invariably it relapses with a resistant disease. We have reported that patient derived ovarian xenografts (PDXs), independently from the degree of the initial response to cisplatin (DDP), show a signif...

Full description

Bibliographic Details
Main Authors: Francesca Ricci, Federica Guffanti, Giovanna Damia, Massimo Broggini
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Molecular Cancer
Subjects:
Ovarian cancer
Second line
Patients derived xenografts
Cisplatin
Drug resistance
Combination chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12943-017-0662-3

Internet

http://link.springer.com/article/10.1186/s12943-017-0662-3

Similar Items